Q2 Performance & Growth Outlook: Zimmer Biomet reported a 2.8% organic constant currency revenue growth in Q2 2025, with positive contributions from the U.S. Hips (up 5.2%) and Knees (up 1.7%). For the full year, the company raised its organic revenue growth guidance to 3.5%-4.5%, previously 3%-5%, and expects Paragon 28 to contribute an additional 270 basis points.

Adjusted Earnings Guidance: The company increased its adjusted EPS forecast for 2025 to $8.10-$8.30, from $7.90-$8.10, reflecting strong operational efficiencies, reduced tariff impacts, and favorable foreign exchange conditions. This suggests a commitment to profitability in a challenging market environment.

Strategic Acquisitions: The acquisition of Monogram Technologies was highlighted as a pivotal event for the company, aimed at advancing Zimmer Biomet¡¯s robotics capabilities. The deal is expected to be neutral to adjusted EPS between 2025 and 2027, with potential revenue contributions beginning in 2027.